Introduction:

This 25-year longitudinal analysis from the Diabetes Tele-Management System (DTMS®) aimed to evaluate the impact of telemedicine (TM)-based follow-up on achieving lipid targets and preventing cardiovascular (CV) events in people with diabetes (PWD).

Methods:

  • Population: 7,780 PWD
    1. Analysis: Baseline and lipid parameters analyzed on follow-up, CV event predictors via Generalized Estimating Equations (GEE). Median survival time on follow-up calculated for each gender.

Results:

Follow-up adherence showed a sharp droput after the initial 1–2 visits, with a 33% dropout rate, after which it stabilized. The baseline LDL cholesterol was 118 ± 40 mg/dL, which declined significantly to 56 ± 10.38 mg/dL during follow-up. Overall, 91% of participants achieved ADA-recommended lipid targets. The median survival times for follow-up was 3.16 years for females and 2.37 years for males.

Regarding lipid-lowering therapy, 53% of participants were on high-intensity statins, while 37% received moderate-intensity statins. The three most commonly prescribed statins were:

  • Atorvastatin 10 mg (mean LDL: 78 ± 20.3 mg/dL)
  • Atorvastatin 5 mg (mean LDL: 57 ± 9 mg/dL)
  • Rosuvastatin 5 mg (mean LDL: 67 ± 24 mg/dL)

Only 3% of the cohort experienced CV events.

On GEE analysis, age (OR = 1.00093, p < 0.001) and low HDL cholesterol (OR = 0.99995, p = 0.009) were significant predictors of CV events. Female sex was found to be protective (OR = 0.9958, p = 0.015). HbA1c (p = 0.051), systolic blood pressure (p = 0.095), and high-dose statin use (p = 0.093) showed marginal associations, while body mass index, triglycerides, and duration of diabetes were not significantly associated with CV outcomes.

Conclusion:

Over 25 years, TM-based follow-up in the DTMS® had critical role in lipid targets and lower incidence of CV events among PWD. 

ADA 2025, 20-23 June, Chicago







Other Conference Highlights